| Drugs | Clinical trials | Target | References |
| PTK787/ZK 222584 (chloroanilino-pyridylmethyl phthalazine succinate) | Phase III for colorectal cancer Phase I, II for advanced hepatocellular carcinoma patients (in combination with intravenous doxorubicin) | Target VEGFR-3, -2, -1, PDGFR-beta (need new strategies for trials to specifically monitor effects on metastasis) | [210, 211] | CEP-7055 (N, N-dimethyl glycine ester) | Phase I as an oral-administered therapy for various malignancies | Target VEGFR-3, -2, -1 | [212] | BAY 43-9006 (Bi-aryl urea) | Phase III for renal cell carcinoma Phase II for multiple tumor types (e.g., prostate, ovarian, pancreatic, breast, and lung cancers…) | Target VEGFR-3, -2 tyrosine kinase, PDGFR-beta, FGFR-1 | [213] | JNJ-26483327 | Phase I for patients with advanced solid tumors | Multitargeted tyrosine kinase inhibitor, inhibiting kinase of (EGFR)-1, -2, -4; VEGFR-3, Src family (Lyn, Fyn, Yes) | [214] | SU-014813 | Phase I for patients with advance solid tumors | Oral multitargeted tyrosine kinase inhibitor | [215] |
|
|